RPS 116 - Novel imaging biomarkers for assessment, treatment response, and outcome prognostication of cancers
Lectures
1
RPS 116 - Gadoxetic acid MRI for the assessment of HCC response to Yttrium 90 radioembolization: correlation with histopathology
03:52N. Vietti Violi, Lausanne / CH
2
RPS 116 - Metabolic and transcriptomic biomarkers to predict response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma
05:23K. Foley, Llantrisant / UK
3
RPS 116 - 68Ga-PSMA PET-CT for primary staging of prostate cancer and use of SUV Max as metastasis predictor
05:18C. Gatica, Santiago / CL
4
RPS 116 - Gadolinium-loaded calcium phosphate nanoparticles for magnetic resonance imaging of primary hepatocellular carcinoma
03:58N. Zhang, Lishui / CN
5
RPS 116 - Prospective study in patients with high-grade soft tissue sarcomas of extremities and trunk wall undergoing neoadjuvant treatment assessed with MRI: correlation between ADC and pathologic response
05:10C. Buonomenna, Milan / IT
6
RPS 116 - Dual-layer spectral detector CT in comparison with FDG-PET/CT for the assessment of lymphoma activity
04:46K. Gehling, Heidelberg / DE
PEP Subscription Required
This course is only accessible for ESR Premium Education Package subscribers.